Brought to you by 
Editas gets new CRISPR IP from academia
22 Dec 2016
Executive Summary
Editas Medicine Inc. received exclusive worldwide rights to new CRISPR IP from the Broad Institute, Harvard University, Massachusetts Institute of Technology, Wageningen University, the University of Iowa, and the University of Tokyo. The deal operates under Broad/Harvard/MIT's inclusive innovation model, which, under certain circumstances, allows the research institutions to license IP outside of Editas' scope to third parties.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com